| Cash Flow | 2026-03-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|
| Net loss | 42,281 | -20,393 | -44,947 |
| Stock-based compensation expense | -6,607 | 3,010 | 6,149 |
| Depreciation | -2,742 | 1,324 | 2,693 |
| Loss on fixed assets write-off | NaN | 0 | 181 |
| Non-cash lease expense | -2,601 | 1,272 | 2,664 |
| Accretion of discounts on available-for-sale marketable securities | -2,170 | 705 | 1,825 |
| Deferred revenue and collaboration advance | NaN | -7,574 | -10,417 |
| Change in fair value of long-term investments | NaN | 0 | 1,292 |
| Income tax payable | NaN | NaN | 0 |
| Amortization of non-cash collaboration revenue | -212 | 125 | 87 |
| Accounts receivable | -8 | 87 | -384 |
| Prepaid expenses and other assets | 3,597 | -1,140 | -2,687 |
| Accounts payable | 87 | -1,576 | 2,284 |
| Deferred revenue | -748 | NaN | NaN |
| Accrued expenses and other current liabilities | -3,576 | 4,023 | -2,476 |
| Operating lease liabilities | 2,675 | -1,328 | -2,818 |
| Other non-current liabilities | 91 | -234 | 143 |
| Net cash used in operating activities | 44,171 | -21,253 | -44,093 |
| Purchases of property and equipment | -464 | 74 | 415 |
| Proceeds from sale of property and equipment | NaN | 0 | 37 |
| Purchases of available-for-sale marketable securities | -10,111 | 6,063 | 40,796 |
| Maturities of available-for-sale marketable securities | -77,715 | 33,500 | 84,974 |
| Net cash provided by investing activities | -67,177 | 27,363 | 43,800 |
| Proceeds from issuance of common stock upon initial public offering, net of underwriting discounts and commissions and other offering costs | NaN | NaN | 0 |
| Proceeds from issuance of common stock under the equity incentive plan and espp | NaN | 109 | NaN |
| Payment of deferred financing costs | -512 | 187 | 352 |
| Proceeds from issuance of common stock under espp | NaN | NaN | 109 |
| Net cash used in financing activities | 403 | -187 | -243 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | -22,603 | 5,923 | -536 |
| Cash, cash equivalents and restricted cash at beginning of period | 38,021 | 32,634 | NaN |
| Cash, cash equivalents and restricted cash at end of period | 29,699 | 38,021 | NaN |
Metagenomi Therapeutics, Inc. (MGX)
Metagenomi Therapeutics, Inc. (MGX)